tetano
Editor, Senior Moderator
J Virol
. 2022 Aug 4;e0048022.
doi: 10.1128/jvi.00480-22. Online ahead of print.
Structural Study of SARS-CoV-2 Antibodies Identifies a Broad-Spectrum Antibody That Neutralizes the Omicron Variant by Disassembling the Spike Trimer
Wuqiang Zhan[SUP] #[/SUP][SUP] 1 2 [/SUP], Xiaolong Tian[SUP] #[/SUP][SUP] 1 3 [/SUP], Xiang Zhang[SUP] #[/SUP][SUP] 1 2 [/SUP], Shenghui Xing[SUP] #[/SUP][SUP] 1 [/SUP], Wenping Song[SUP] 1 3 [/SUP], Qianying Liu[SUP] 1 [/SUP], Aihua Hao[SUP] 1 2 [/SUP], Yuxia Hu[SUP] 1 2 [/SUP], Meng Zhang[SUP] 1 2 [/SUP], Tianlei Ying[SUP] 1 3 [/SUP], Zhenguo Chen[SUP] 1 2 [/SUP], Fei Lan[SUP] 1 [/SUP], Lei Sun[SUP] 1 2 [/SUP]
Affiliations
Abstract
The continuous emergence of novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants poses new challenges in the fight against the coronavirus disease 2019 (COVID-19) pandemic. The newly emerging Omicron strain caused serious immune escape and raised unprecedented concern all over the world. The development of an antibody targeting a conserved and universal epitope is urgently needed. A subset of neutralizing antibodies (NAbs) against COVID-19 from convalescent patients were isolated in our previous study. In this study, we investigated the accommodation of these NAbs to SARS-CoV-2 variants of concern (VOCs), revealing that IgG 553-49 neutralizes pseudovirus of the SARS-CoV-2 Omicron variant. In addition, we determined the cryo-electron microscopy (cryo-EM) structure of the SARS-CoV-2 spike (S) protein complexed with three monoclonal antibodies targeting different epitopes, including 553-49, 553-15, and 553-60. Notably, 553-49 targets a novel conserved epitope and neutralizes the virus by disassembling S trimers. IgG 553-15, an antibody that neutralizes all of the VOCs except Omicron, cross-links two S trimers to form a trimer dimer, demonstrating that 553-15 neutralizes the virus by steric hindrance and virion aggregation. These findings suggest the potential to develop 553-49 and other antibodies targeting this highly conserved epitope as promising therapeutic reagents for COVID-19. IMPORTANCE The emergence of the Omicron strain of SARS-CoV-2 caused higher immune escape, raising unprecedented concerns about the effectiveness of antibody therapies and vaccines. In this study, we identified a SARS-CoV-2 neutralizing antibody, 553-49, which neutralizes all variants by targeting a completely conserved novel epitope. In addition, we revealed that IgG 553-15 neutralizes SARS-CoV-2 by cross-linking virions and that 553-60 functions by blocking receptor binding. Comparison of different receptor binding domain (RBD) epitopes revealed that the 553-49 epitope is hidden in the S trimer and keeps a high degree of conservation during SARS-CoV-2 evolution, making 553-49 a promising therapeutic reagent against the emerging Omicron and future variants of SARS-CoV-2.
Keywords: COVID-19; NAb; Omicron variant; SARS-CoV-2; neutralizing antibody.
. 2022 Aug 4;e0048022.
doi: 10.1128/jvi.00480-22. Online ahead of print.
Structural Study of SARS-CoV-2 Antibodies Identifies a Broad-Spectrum Antibody That Neutralizes the Omicron Variant by Disassembling the Spike Trimer
Wuqiang Zhan[SUP] #[/SUP][SUP] 1 2 [/SUP], Xiaolong Tian[SUP] #[/SUP][SUP] 1 3 [/SUP], Xiang Zhang[SUP] #[/SUP][SUP] 1 2 [/SUP], Shenghui Xing[SUP] #[/SUP][SUP] 1 [/SUP], Wenping Song[SUP] 1 3 [/SUP], Qianying Liu[SUP] 1 [/SUP], Aihua Hao[SUP] 1 2 [/SUP], Yuxia Hu[SUP] 1 2 [/SUP], Meng Zhang[SUP] 1 2 [/SUP], Tianlei Ying[SUP] 1 3 [/SUP], Zhenguo Chen[SUP] 1 2 [/SUP], Fei Lan[SUP] 1 [/SUP], Lei Sun[SUP] 1 2 [/SUP]
Affiliations
- PMID: 35924918
- DOI: 10.1128/jvi.00480-22
Abstract
The continuous emergence of novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants poses new challenges in the fight against the coronavirus disease 2019 (COVID-19) pandemic. The newly emerging Omicron strain caused serious immune escape and raised unprecedented concern all over the world. The development of an antibody targeting a conserved and universal epitope is urgently needed. A subset of neutralizing antibodies (NAbs) against COVID-19 from convalescent patients were isolated in our previous study. In this study, we investigated the accommodation of these NAbs to SARS-CoV-2 variants of concern (VOCs), revealing that IgG 553-49 neutralizes pseudovirus of the SARS-CoV-2 Omicron variant. In addition, we determined the cryo-electron microscopy (cryo-EM) structure of the SARS-CoV-2 spike (S) protein complexed with three monoclonal antibodies targeting different epitopes, including 553-49, 553-15, and 553-60. Notably, 553-49 targets a novel conserved epitope and neutralizes the virus by disassembling S trimers. IgG 553-15, an antibody that neutralizes all of the VOCs except Omicron, cross-links two S trimers to form a trimer dimer, demonstrating that 553-15 neutralizes the virus by steric hindrance and virion aggregation. These findings suggest the potential to develop 553-49 and other antibodies targeting this highly conserved epitope as promising therapeutic reagents for COVID-19. IMPORTANCE The emergence of the Omicron strain of SARS-CoV-2 caused higher immune escape, raising unprecedented concerns about the effectiveness of antibody therapies and vaccines. In this study, we identified a SARS-CoV-2 neutralizing antibody, 553-49, which neutralizes all variants by targeting a completely conserved novel epitope. In addition, we revealed that IgG 553-15 neutralizes SARS-CoV-2 by cross-linking virions and that 553-60 functions by blocking receptor binding. Comparison of different receptor binding domain (RBD) epitopes revealed that the 553-49 epitope is hidden in the S trimer and keeps a high degree of conservation during SARS-CoV-2 evolution, making 553-49 a promising therapeutic reagent against the emerging Omicron and future variants of SARS-CoV-2.
Keywords: COVID-19; NAb; Omicron variant; SARS-CoV-2; neutralizing antibody.